Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Welfol-D3 is an oral combination pharmaceutical product developed by Solis Pharms, containing methylcobalamin (1500 mcg), pyridoxine (20 mg), folic acid (5 mg), and cholecalciferol (2000 IU). This formulation is designed to address nutritional deficiencies and support neurological and bone health. Methylcobalamin, a bioactive form of Vitamin B12, is essential for myelin sheath maintenance and DNA synthesis. Pyridoxine (Vitamin B6) serves as a critical cofactor in neurotransmitter synthesis and amino acid metabolism. Folic acid (Vitamin B9) is vital for nucleotide biosynthesis and the regulation of homocysteine levels. Cholecalciferol (Vitamin D3) promotes calcium absorption and bone mineralization by activating the Vitamin D receptor. The product is primarily indicated for the management of peripheral neuropathy, megaloblastic anemia, and vitamin D deficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylcobalamin + pyridoxine + folic acid + cholecalciferol.